In agreement with this, in a more recent study including 102 patients with histologically confirmed SCLC at stages I–III, high FOXP3 expression showed longer relapse-free survival times than the low-level group (41.2 months versus 14 months, p = 0.008) [26]. Here, FOXP3 is linked to small cell lung carcinoma.